Efficacy of Extracellular Vesicle-Rich Conditioned Medium from Adipose Tissue-Derived Human Mesenchymal Stem Cells for Androgenetic Alopecia: A Single-Center Intervention Study (EVERIMEN Study)

未提供0 个研究点目标入组 10 人开始时间: 待定最近更新: 2025年3月26日

适应症

试验速览

暂无简介。

•Patients diagnosed with androgenetic alopecia in males
•Patients diagnosed with Hamilton-Norwood classification type II Vertex, III Vertex, IV, and V
•Patients who have used minoxidil, 5-alpha reductase inhibitors, or both in the past (including ongoing use) but are dissatisfied with the results and wish to receive stem cell supernatant fluid
•Patients aged 18 years or older
•Patients who have given written informed consent

•Patients undergoing treatment for malignant tumours
•Patients with concurrent hair loss other than androgenetic alopecia
•Patients who have previously undergone stem cell supernatant solution treatment for the scalp
•Patients who have started or changed their treatment for androgenetic alopecia within 6 months prior to obtaining consent
•Patients currently participating in another clinical trial
•Patients deemed inappropriate as subjects by the principal investigator (subinvestigator)

Change in scalp hair density from baseline to 32 weeks of treatment (strands/cm2)

Changes in scalp hair density
Modified Global Photographic Assessment (MGPA) score(16, 32 and 52 weeks post-treatment)
Changes in Dermatology Life Quality Index (DLQI)
Subject satisfaction with treatment(32 and 52 weeks)

发起方

未提供